Trial Profile

A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Subjects with Locally Advanced or Metastatic NSCLC Harboring EGFR And/or HER2 Mutations (SOLARA)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 16 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

21 May 2026 According to the BlossomHill Therapeutics media release, data from this trial will be presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on Tuesday, June 2, 2026.
21 May 2026 Results presented in the BlossomHill Therapeutics media release.
24 Oct 2025 According to the BlossomHill Therapeutics media release, company look forward to sharing more findings from the Phase 1/2 SOLARA trial in 2026

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com